Strategies for Therapy of MPS and Related Diseases
MPS 及相关疾病的治疗策略
基本信息
- 批准号:6359299
- 负责人:
- 金额:$ 2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-06-21 至 2002-05-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant):
This application is for the support of a meeting on "Strategies for Therapy of
MPS and Related Diseases" to be held at the University of California Los
Angeles on June 21-24, 2001. The MPS (mucopolysaccharidoses) are heritable
diseases of lysosomal function that are chronic, progressive, involve numerous
organs and cause a variety of disabilities as well as early death. Recent
availability of cloned genes, recombinant enzymes and animal models has
generated a burst of research activity in these and closely related lysosomal
storage diseases, including clinical trials of enzyme replacement therapy. At
the same time, many difficulties in altering the course of these disorders have
become apparent, the most vexing of which is the difficulty of altering the
neurologic component of the disease. The goals of the meeting are to a)
disseminate new findings on pathogenesis, including newly identified genes and
the role of macrophage-derived cells in neuronal disease, and b) to discuss
major issues in the area of therapy, such as ways to cross the blood-brain
barrier, enzyme targeting, optimization of vectors for gene therapy, immune
reactions, substrate deprivation, and stem cell therapy. We will invite 25-30
investigators at the cutting edge of the field to be the core speakers, and
expect a total of about a hundred professional attendees. Not all the speaker
slots have been filled, to permit selection of additional speakers from
abstracts as well on the basis of new scientific developments. This meeting
will be held in conjunction with the annual meeting of the National MPS Society
Inc., which expects an attendance of about 200 families. The scientific
meetings will be open to the families and vice-versa, and there will be a
number of formal and informal opportunities for interaction between the two
groups. The ultimate goal of this meeting is to facilitate and accelerate
research for effective therapy of the MPS and related lysosomal storage
diseases.
描述(由申请人提供):
此应用程序是支持一个会议上"的治疗策略,
MPS和相关疾病"将在加州洛杉矶大学举行
洛杉矶,2001年6月21日至24日。MPS(粘多糖沉积症)是可遗传的
溶酶体功能疾病是慢性的、进行性的,涉及许多
器官,并导致各种残疾以及过早死亡。最近
克隆基因、重组酶和动物模型的可用性,
在这些与溶酶体密切相关的研究中产生了一系列的研究活动,
储存疾病,包括酶替代疗法的临床试验。在
与此同时,改变这些疾病的过程中存在许多困难,
其中,最大的困难,就是改变。
疾病的神经系统部分。会议的目标是a)
传播关于发病机制的新发现,包括新发现的基因,
巨噬细胞源性细胞在神经元疾病中的作用,以及B)讨论
治疗领域的主要问题,如如何穿过血脑
屏障,酶靶向,基因治疗载体优化,免疫
反应、底物剥夺和干细胞治疗。我们将邀请25 - 30
研究人员在该领域的前沿是核心发言人,
预计共有约一百名专业人士参加。不是所有的演讲者
空缺已经填补,以便从下列国家中挑选更多的发言者:
在新的科学发展的基础上也进行了摘要。本次会议
将与全国MPS协会年会同时举行
股份有限公司、预计将有200个家庭参加。科学
会议将开放给家庭,反之亦然,并将有一个
两人之间进行正式和非正式互动的机会数目
组这次会议的最终目的是促进和加快
MPS和相关溶酶体贮积症的有效治疗研究
疾病
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ELIZABETH NEUFELD其他文献
ELIZABETH NEUFELD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ELIZABETH NEUFELD', 18)}}的其他基金
Aptamer-directed crossing of the blood barrier for enzyme therapy of LSDs
适体引导穿越血屏障用于 LSD 酶疗法
- 批准号:
7455147 - 财政年份:2005
- 资助金额:
$ 2万 - 项目类别:
Aptamer-directed crossing blood barrier enzyme therapy
适体引导的跨血屏障酶疗法
- 批准号:
7015911 - 财政年份:2005
- 资助金额:
$ 2万 - 项目类别:
Aptamer-directed crossing of the blood barrier for enzyme therapy of LSDs
适体引导穿越血屏障用于 LSD 酶疗法
- 批准号:
7285603 - 财政年份:2005
- 资助金额:
$ 2万 - 项目类别:
Aptamer-directed crossing of the blood barrier for enzyme therapy of LSDs
适体引导穿越血屏障用于 LSD 酶疗法
- 批准号:
7126425 - 财政年份:2005
- 资助金额:
$ 2万 - 项目类别:
Aptamer-directed crossing of BBB therapy of MPS 111B
MPS 111B 的 BBB 疗法适体定向交叉
- 批准号:
6759811 - 财政年份:2004
- 资助金额:
$ 2万 - 项目类别:
Aptamer-directed crossing of BBB therapy of MPS 111B
MPS 111B 的 BBB 疗法适体定向交叉
- 批准号:
6864843 - 财政年份:2004
- 资助金额:
$ 2万 - 项目类别:
ENZYME AND GENE THERAPY OF MPS I IN ANIMAL MODELS
MPS I 在动物模型中的酶和基因治疗
- 批准号:
2899468 - 财政年份:1987
- 资助金额:
$ 2万 - 项目类别:
ENZYME AND GENE THERAPY OF MPS I IN ANIMAL MODELS
MPS I 在动物模型中的酶和基因治疗
- 批准号:
2458754 - 财政年份:1987
- 资助金额:
$ 2万 - 项目类别:
ENZYME AND GENE THERAPY OF MPS I IN ANIMAL MODELS
MPS I 在动物模型中的酶和基因治疗
- 批准号:
6176442 - 财政年份:1987
- 资助金额:
$ 2万 - 项目类别:
相似海外基金
Cellular Phenotypes of Genetic Variants in Mucopolysaccharidosis
粘多糖贮积症遗传变异的细胞表型
- 批准号:
10638709 - 财政年份:2023
- 资助金额:
$ 2万 - 项目类别:
Pulmonary endothelium targeted adenoviral gene therapy for the correction of mucopolysaccharidosis type I
肺内皮靶向腺病毒基因治疗纠正 I 型粘多糖贮积症
- 批准号:
10678053 - 财政年份:2023
- 资助金额:
$ 2万 - 项目类别:
PROJECT 3: MUCOPOLYSACCHARIDOSIS TYPE 1 (MPS1)
项目 3:粘多糖中毒 1 型 (MPS1)
- 批准号:
10668620 - 财政年份:2023
- 资助金额:
$ 2万 - 项目类别:
Combination Gene Therapy for Treatment of Canine Mucopolysaccharidosis Type I
治疗犬 I 型粘多糖贮积症的组合基因疗法
- 批准号:
10582337 - 财政年份:2023
- 资助金额:
$ 2万 - 项目类别:
Cellular phenotype of mucopolysaccharidosis II for studies of genomic variants
用于基因组变异研究的粘多糖贮积症 II 的细胞表型
- 批准号:
10442244 - 财政年份:2022
- 资助金额:
$ 2万 - 项目类别:
Enhancement of Newborn Screening Diagnostic Paradigms to Improve the Efficacy of Treatment for Krabbe Disease, Pompe Disease, and Mucopolysaccharidosis Type 1
加强新生儿筛查诊断范式以提高克拉伯病、庞贝病和 1 型粘多糖贮积症的治疗效果
- 批准号:
10366620 - 财政年份:2022
- 资助金额:
$ 2万 - 项目类别:
Cellular phenotype of mucopolysaccharidosis II for studies of genomic variants
用于基因组变异研究的粘多糖贮积症 II 的细胞表型
- 批准号:
10589929 - 财政年份:2022
- 资助金额:
$ 2万 - 项目类别:
Enhancement of Newborn Screening Diagnostic Paradigms to Improve the Efficacy of Treatment for Krabbe Disease, Pompe Disease, and Mucopolysaccharidosis Type 1
加强新生儿筛查诊断范式以提高克拉伯病、庞贝病和 1 型粘多糖贮积症的治疗效果
- 批准号:
10594424 - 财政年份:2022
- 资助金额:
$ 2万 - 项目类别:
Evaluation of clinical outcome assessment (COA) and potential biomarkers to Facilitate Interventionaltrial for Mucopolysaccharidosis IIID Patients
临床结果评估 (COA) 和潜在生物标志物的评估,以促进粘多糖贮积症 IIID 患者的介入试验
- 批准号:
10325321 - 财政年份:2021
- 资助金额:
$ 2万 - 项目类别:
NEWBORN SCREENING PILOT STUDIES FOR MUCOPOLYSACCHARIDOSIS TYPE II
新生儿粘多糖增多症 II 型筛查试点研究
- 批准号:
10937982 - 财政年份:2021
- 资助金额:
$ 2万 - 项目类别:














{{item.name}}会员




